These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Development of growth hormone secretagogues. Smith RG Endocr Rev; 2005 May; 26(3):346-60. PubMed ID: 15814848 [TBL] [Abstract][Full Text] [Related]
8. Treatment of obese subjects with the oral growth hormone secretagogue MK-677 affects serum concentrations of several lipoproteins, but not lipoprotein(a). Svensson J; Jansson JO; Ottosson M; Johannsson G; Taskinen MR; Wiklund O; Bengtsson BA J Clin Endocrinol Metab; 1999 Jun; 84(6):2028-33. PubMed ID: 10372705 [TBL] [Abstract][Full Text] [Related]
9. Update on new therapeutic options for the somatopause. Ceda GP; Dall'Aglio E; Morganti S; Denti L; Maggio M; Lauretani F; Andrea A; Ceresini G; Cattabiani C; Valenti G Acta Biomed; 2010; 81 Suppl 1():67-72. PubMed ID: 20518193 [TBL] [Abstract][Full Text] [Related]
10. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. Svensson J; Lönn L; Jansson JO; Murphy G; Wyss D; Krupa D; Cerchio K; Polvino W; Gertz B; Boseaus I; Sjöström L; Bengtsson BA J Clin Endocrinol Metab; 1998 Feb; 83(2):362-9. PubMed ID: 9467542 [TBL] [Abstract][Full Text] [Related]
11. Identification of a new G-protein-linked receptor for growth hormone secretagogues. Pong SS; Chaung LY; Dean DC; Nargund RP; Patchett AA; Smith RG Mol Endocrinol; 1996 Jan; 10(1):57-61. PubMed ID: 8838145 [TBL] [Abstract][Full Text] [Related]
12. What is the role of vaptans in routine clinical nephrology? Bichet DG Clin J Am Soc Nephrol; 2012 May; 7(5):700-3. PubMed ID: 22516285 [No Abstract] [Full Text] [Related]
14. [New growth hormone secretagogues: from physiology to the first therapeutic applications]. Ahnfelt-Rønne I; Haahr PM Arch Pediatr; 1998; 5 Suppl 4():390S-396S. PubMed ID: 9853090 [TBL] [Abstract][Full Text] [Related]
15. Nonpeptide and peptide growth hormone secretagogues act both as ghrelin receptor agonist and as positive or negative allosteric modulators of ghrelin signaling. Holst B; Brandt E; Bach A; Heding A; Schwartz TW Mol Endocrinol; 2005 Sep; 19(9):2400-11. PubMed ID: 15905359 [TBL] [Abstract][Full Text] [Related]
16. Letter: Vaptans for the treatment of hyponatraemia and ascites in patients with cirrhosis. Karaahmet F; Coban S; Başar O; Yuksel O Aliment Pharmacol Ther; 2012 Dec; 36(11-12):1103-4; author reply 1104. PubMed ID: 23130775 [No Abstract] [Full Text] [Related]
17. The use of growth hormone (GH) secretagogues in the diagnosis of GH deficiency in humans. Peino R; Leal A; Garcia-Mayor RV; Cordido F; Micic D; Kopeschaar H; Dieguez C; Casanueva FF Growth Horm IGF Res; 1999 Apr; 9 Suppl A():101-5. PubMed ID: 10429891 [No Abstract] [Full Text] [Related]
18. Discrepancy between serum leptin values and total body fat in response to the oral growth hormone secretagogue MK-677. Svensson J; Carlsson B; Carlsson LM; Jansson JO; Bengtsson BA Clin Endocrinol (Oxf); 1999 Apr; 50(4):451-6. PubMed ID: 10468903 [TBL] [Abstract][Full Text] [Related]
19. Clinical and experimental effects of growth hormone secretagogues on various organ systems. Svensson JA; Bengtsson B Horm Res; 1999; 51 Suppl 3():16-20. PubMed ID: 10592439 [TBL] [Abstract][Full Text] [Related]